- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03104283
Apatinib for the Elderly Advanced Gastric Cancer
A Multicenter, Single-arm, Phase Ⅱ Clinical Trial of Apatinib Monotherapy in Elderly Patients With Advanced Gastric Cancer(GC)
Descripción general del estudio
Descripción detallada
The trial is funded by Chinese Society of Clinical Oncology-Beijing Xisike Clinical Oncology Research Fundation. The trial is prepared to be registered on the clinicaltrail.gov.
Quality assurance plan: Every participant is enrolled or excluded by two practiced investigators. And two investigators participate in all steps of the trail, including the record of the data, which is compared by the investigators. If the data is consistent, the investigators would record the data; if not, the data would be checked and decided by the two investigators. All the steps and data are site monitored and audited by the staff of research and financial department of Affliated Hospital of Qinghai University.
Data check: The investigators compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry.
Source data verification: The investigators assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources, including medical records and electronic case report forms.
Data dictionary that contains detailed descriptions of each variable used by the registry, including the source of the variable, coding information, and normal ranges if relevant.
Standard Operating Procedures to address registry operations and analysis activities, such as participants recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. All registry operations would be done according to specific steps, and by two practiced investigators.
Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect. According to the formula to differ advantages and disadvantages, the investigators need at least 47 participants to take part in the trail. The investigators can recruit about 20 participants every year according to previous experiences, so the investigators should recruit about two years.
Plan for missing data: The investigators would collect as much data as possible, and the investigators exclude the participants who cannot cooperate on recruitment. And the investigators manage situations according to statistical principles where variables are reported as missing, unavailable, non-reported, uninterpretable, or considered missing because of data inconsistency or out-of-range results.
Statistical analysis plan: Statistical analyses would be performed by using SPSS software, version 13.0 (SPSS Inc., IL, USA). Survival analysis would be performed using Kaplan-Meier methodology. Fisher's exact test would be used to analyze the efficacy of treatment. Cox proportional hazards model would be used for multivariate analysis. The level of significance is defined as P < 0.05.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Qinghai
-
Xining, Qinghai, Porcelana, 810000
- Affiliated Hospital of Qinghai University
-
Xining, Qinghai, Porcelana, 810000
- People's Hospital of Qinghai Province
-
Xining, Qinghai, Porcelana, 810000
- Qinghai Red Cross Hospital
-
Xining, Qinghai, Porcelana, 810000
- The Fifth People's Hospital of Qinghai Province
-
-
Shanxi
-
Yangquan, Shanxi, Porcelana, 045000
- Yangquan No.1 People's Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Elderly patients (aged ≥ 60 years) with histologically confirmed advanced adenocarcinoma of the stomach or gastroesophageal junction;
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
- Progression with or intolerance to one or more lines of chemotherapy;
- At least one measurable lesion as defined by RECIST 1.1;
- With acceptable hematologic, cardiac, hepatic, pulmonary and renal function;
- Can take apatinib orally;
- Estimated life expectancy ≥ 3 months.
Exclusion Criteria:
- Patients cannot take apatinib orally for any reason;
- Patients with uncontrolled central nervous system (CNS) metastases;
- Patients with massive hydrothorax or ascites;
- Proteinuria 2+ or 24-hour urinary protein ≥ 1g;
- Newly-happened traumatism or pathological fracture;
- Estimated life expectancy ˂ 3 months;
- Received chemotherapy in the past 28 days before enrollment;
- Patients with uncontrolled blood pressure on medication (≥ 140/90 mmHg);
- Patients with bleeding tendency, receiving thrombolytics or anticoagulants, receiving intravenous antibiotic treatment, had received bevacizumab or other VEGF TKIs before, or with other primary malignancy (except basal cell skin cancer or cervical carcinoma in situ).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Apatinib Group
take apatinib orally (500mg/d or 250mg/d, once a day, continuously )
|
take apatinib orally until disease progression or appearance of unbearable toxicity
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-free survival (PFS)
Periodo de tiempo: 1 year
|
PFS was defined to be the time from registration to the date of disease progress sion or death resulting from any cause.
|
1 year
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective response rate (ORR)
Periodo de tiempo: 1 year
|
ORR was defined as the proportion of eligible patients who achieved a confirmed complete response(CR )or partial response (PR) by RECIST 1.1 criteria evaluated by the investigators.
|
1 year
|
|
Disease control rate (DCR)
Periodo de tiempo: 1 year
|
DCR was defined as the proportion of patients who achieved CR, PR and stable disease (SD) for at least 8 weeks.
|
1 year
|
|
Overall survival (OS)
Periodo de tiempo: 1 year
|
OS was defined to be the time from registration to the date of death resulting from any cause or the last follow-up visit.
|
1 year
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias
- Neoplasias por sitio
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del Estómago
- Neoplasias de Estómago
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antineoplásicos
- Inhibidores de la proteína quinasa
- Apatinib
Otros números de identificación del estudio
- AHQU-2017001
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer gástrico
-
Istanbul Aydın UniversityTerminado
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
Ensayos clínicos sobre Apatinib
-
Song PengAún no reclutandoCarcinoma hepatocelular no resecablePorcelana
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Aún no reclutandoCarcinoma hepatocelular (CHC) | Carcinoma hepatocelular irresecable (CHC) | Cáncer de hígado en adultosPorcelana
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Aún no reclutandoMelanoma de las mucosas
-
Linhui PengReclutamientoCarcinoma hepatocelular (CHC) | Efecto de la quimioterapiaPorcelana
-
Beijing Friendship HospitalReclutamientoAdenocarcinoma de estómago | Adenocarcinoma de unión GE | AdebrelimabPorcelana
-
Fujian Medical UniversityAún no reclutandoCáncer gástrico | CirugíaPorcelana
-
The First Affiliated Hospital of Zhengzhou UniversityReclutamientoCáncer gástrico avanzado | SHR1701Porcelana
-
First Affiliated Hospital of Chongqing Medical...Aún no reclutandoInmunomodulación | Carcinomas hepatocelulares | Resistencia a la inmunoterapia | Reutilización de MedicamentosPorcelana
-
Guangzhou Virotech Pharmaceutical Co., Ltd.Reclutamiento
-
Peking University Cancer Hospital & InstituteAún no reclutandoCarcinoma de pulmón de células pequeñasPorcelana